{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-005511","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2025-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.576625+00:00","generated_at":"2026-05-23T10:09:28.857926+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Propanc Biopharma raises ~$180k via convertible notes and board loan; conversion at deep discounts","bullets":["$55k face convertible note issued at $50k (original issue discount) to GS Capital Partners; conversion price $5.00, drops to $2.50 if stock below $4 for 5 days.","$79.2k convertible note issued with 15% one-time interest; conversion at 65% of lowest trading price after default (35% discount).","$63k AUD loan from board member at 12% interest, due June 30, 2025; all proceeds for working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-005511","json":"https://secwatch.observer/filing/0001641172-25-005511.json","markdown":"https://secwatch.observer/filing/0001641172-25-005511.md","text":"https://secwatch.observer/filing/0001641172-25-005511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000164117225005511/0001641172-25-005511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000164117225005511/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T10:09:28.857926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}